Middle East & Africa Radiopharmaceutical Theranostics Market

The Middle East & Africa radiopharmaceutical theranostics market was valued at US$ 89.44 million in 2022 and is expected to reach US$ 157.30 million by 2028; it is estimated to register a CAGR of 9.9% from 2022 to 2028.

Rising Incidence of Cancer fuel the Middle East & Africa Radiopharmaceutical Theranostics Market

The most common types of cancer are breast, lung, colon, rectum, and prostate. As people age, they become immunocompromised and often succumb to cancer risks. Poor lifestyles, longer working hours, increasingly stressful lives, smoking, alcohol consumption, contraceptive use, nulliparity, and reduced breastfeeding all contribute to breast cancer incidence. Theranostics is the combination of therapeutic and diagnostic techniques that utilize a suitable radiopharmaceutical agent. For example, radioiodine has a well-known theranostic application in diagnosing and treating differentiated thyroid cancer. Several radiopharmaceutical theranostic pairs are available for breast cancer applications. These pairs include ^43/44Sc/⁴⁷Sc, ⁶⁴Cu/⁶⁷Cu, ⁸³Sr/⁸⁹Sr, ^86Y/90Y, ¹¹⁰In/¹¹¹In, ^124I/131I, ¹⁵²Tb/¹⁶¹Tb, ¹⁵²Tb/¹⁴⁹Tb, ⁶⁸Ga/¹⁷⁷Lu, and ⁹⁰Y/¹⁷⁷Lu. ¹²³I/¹³¹I is a well-known example of theranostic pair that is used in high-quality single-photon emission computerized tomography (SPECT)/CT for pre- and post-therapeutic assessment of thyroid cancer. Malignant gliomas are deadly tumors with the availability of only a few therapeutic options. ⁸⁹Zr- and ¹⁷⁷Lu-labeled Lumi804-αCD11b is a promising theranostic technique intended for monitoring and reducing tumor-associated myeloid cells (TAMCs) in gliomas and improving immunotherapy outcomes. Further, theranostics are incorporated in radiometals for PET imaging and targeted radiopharmaceutical therapy (TRT). DOTA-octreotate (dotatate) radiolabeled with Lu-177 (177Lu-dotatate: Lutathera) or Ga-68 (68Ga-dotatate: NetSpot) are approved by the Food and Drug Administration (FDA) for targeted radiopharmaceutical therapy (TRT) and positron emission tomography (PET) imaging. Thus, a radiopharmaceutical theranostic approach has unprecedented value in diagnosing and treating different types of cancer, which fuels the overall market growth.

Middle East & Africa Radiopharmaceutical Theranostics Market Overview

The Middle East & Africa radiopharmaceutical theranostics market is segmented into the Saudi Arabia, South Africa, UAE, and the rest of Middle East & Africa. The market growth in this region is due to the increasing incidences of chronic diseases, presence of supportive government plans, growing strategic initiatives by the market players, and development of innovative radiotherapies. The major factors for diabetes are obesity, unhealthy lifestyle, increased life expectancy, increased healthcare expenditures, and genetic susceptibility. Thus, increasing cardiovascular diseases due to rising diabetes condition in Saudi Arabia is driving the growth of radiopharmaceutical theranostics market.

Middle East & Africa Radiopharmaceutical Theranostics Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Radiopharmaceutical Theranostics Strategic Insights

Strategic insights for the Middle East & Africa Radiopharmaceutical Theranostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East & Africa Radiopharmaceutical Theranostics Report Scope

Middle East & Africa Radiopharmaceutical Theranostics Regional Insights

The geographic scope of the Middle East & Africa Radiopharmaceutical Theranostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Middle East & Africa Radiopharmaceutical Theranostics Market Segmentation 

The Middle East & Africa radiopharmaceutical theranostics market is segmented based on product type, radioisotype, source, application, indication, end user, and country. Based on product type, the Middle East & Africa radiopharmaceutical theranostics market is segmented into alpha emitters, beta emitters, and Positron Emission Tomography (PET) tracers. The Positron Emission Tomography (PET) tracers segment held the largest market share in 2022.

Based on radioisotype, the Middle East & Africa radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held the largest market share in 2022.

Based on source, the Middle East & Africa radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held a larger market share in 2022.

Based on application, the Middle East & Africa radiopharmaceutical theranostics market is bifurcated into targeted therapeutic [Rx] and Companion Diagnostic [CDx]. The targeted therapeutic [Rx] segment held a larger market share in 2022.

Based on indication, the Middle East & Africa radiopharmaceutical theranostics market is segmented into oncology, cardiology, neurology, and others. The oncology segment held the largest market share in 2022.

Based on end user, the Middle East & Africa radiopharmaceutical theranostics market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held the largest market share in 2022.

Based on country, the Middle East & Africa radiopharmaceutical theranostics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa radiopharmaceutical theranostics market share in 2022.

Bayer AG; Curium; Telix Pharmaceuticals Ltd.; and Siemens Healthineers are some of the leading companies operating in the Middle East & Africa radiopharmaceutical theranostics market.